Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy

Cancer

Volumn 117, Issue 17, 2011, Pages 3953-3962

  Salonia, Andrea ^a   Gallina, Andrea ^a   Briganti, Alberto ^a   Abdollah, Firas ^a   Suardi, Nazareno ^a   Capitanio, Umberto ^a   Colombo, Renzo ^a   Freschi, Massimo ^a   Rigatti, Patrizio ^a   Montorsi, Francesco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

high risk; hypogonadism; pathologic grade; pathologic stage; prostate cancer; radical prostatectomy; testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BODY MASS; CANCER GRADING; CANCER INVASION; CANCER STAGING; CAUCASIAN; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; TESTOSTERONE BLOOD LEVEL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE;

EID: 79960258328     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25985     Document Type: Article

References (50)

1. Cunha GR, Ricke W, Thomson A, et al. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol. 2004; 92: 221-236. (Pubitemid 40136583)
2. Colombel M, Filleur S, Fournier P, et al. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res. 2005; 65: 300-308. (Pubitemid 40070822)
3. Garcia JM, Li H, Mann D, et al. Hypogonadism in male patients with cancer. Cancer. 2006; 106: 2583-2591.
4. Wiren S, Stocks T, Rinaldi S, et al. Androgens and prostate cancer risk: a prospective study. Prostate. 2007; 67: 1230-1237. (Pubitemid 47221890)
5. Weiss JM, Huang WY, Rinaldi S, et al. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer. 2008; 122: 2345-2350. (Pubitemid 351542341)
6. Isbarn H, Pinthus JH, Marks LS, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol. 2009; 56: 48-56.
7. Heikkila R, Aho K, Heliovaara M, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer. 1999; 86: 312-315. (Pubitemid 29327588)
8. Platz EA, Leitzmann MF, Rifai N, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1262-1269. (Pubitemid 40656478)
9. Endogenous Hormones, Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ,. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008; 100: 170-183. (Pubitemid 351480553)
10. Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK,. Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology. 2009; 73: 356-361.
11. Morgentaler A,. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol. 2009; 181: 972-979.
12. Morgentaler A, Rhoden EL,. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006; 68: 1263-1267. (Pubitemid 44880344)
13. San Francisco IF, Regan MM, Dewolf WC, Olumi AF,. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol. 2006; 175: 1341-1345.
14. Banach-Petrosky W, Jessen WJ, Ouyang X, et al. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res. 2007; 67: 9089-9096. (Pubitemid 47535894)
15. Massengill JC, Sun L, Moul JW, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003; 169: 1670-1675. (Pubitemid 36443468)
16. Imamoto T, Suzuki H, Fukasawa S, et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol. 2005; 47: 308-312. (Pubitemid 40248848)
17. Isom-Batz G, Bianco FJ Jr, Kattan MW, Mulhall JP, Lilja H, Eastham JA,. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005; 173: 1935-1937. (Pubitemid 40675215)
18. Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM,. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol. 2005; 174: 2178-2180. (Pubitemid 41611769)
19. Severi G, Morris HA, MacInnis RJ, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006; 15: 86-91.
20. Ide H, Yasuda M, Nishio K, et al. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels. Anticancer Res. 2008; 28: 2487-2492.
21. Green F, Page D, Fleming I,. American Joint Committee on Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
22. How to Define, Determine, and Utilize Reference Intervals in the Clinical Laboratory; Approved Guidelines. Villanova, PA: National Committee for Clinical Laboratory Standards; 1995.
23. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007; 69: 1095-1101. (Pubitemid 46891611)
24. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract. 2002; 8: 440-456.
25. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004; 89: 5916-5919.
26. Tajar A, Forti G, O'Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010; 95: 1810-1818.
27. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. Eur Urol. 2009; 55: 121-130.
28. Santoro N, Torrens J, Crawford S, et al. Correlates of circulating androgens in mid-life women: the Study of Women's Health across the Nation. J Clin Endocrinol Metab. 2005; 90: 4836-4845. (Pubitemid 41159380)
29. Morgentaler A,. Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur Urol. 2007; 52: 623-625. (Pubitemid 47126171)
30. Pierorazio PM, Ferrucci L, Kettermann A, Longo DL, Metter EJ, Carter HB,. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int. 2010; 105: 884-885.
31. Fodstad P, Bjoro T, Torlakovic G, Fossa SD,. No association of serum gonadal or pituitary hormones with prognostic parameters in stages T1 to T3 PN0M0 prostate cancer. J Urol. 2002; 168: 1188-1192.
32. Hoffman MA, DeWolf WC, Morgentaler A,. Is low serum free testosterone a marker for high grade prostate cancer? J Urol. 2000; 163: 824-827. (Pubitemid 30091624)
33. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001; 47: 52-58. (Pubitemid 32246752)
34. Gallina A, Karakiewicz PI, Hutterer GC, et al. Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. Int J Cancer. 2007; 121: 791-795. (Pubitemid 47106208)
35. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004; 22: 439-445. (Pubitemid 41079772)
36. Banez LL, Sun L, Trock BJ, et al. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol. 2009; 182: 491-496.
37. Vermeulen A, Verdonck L, Kaufman JM,. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999; 84: 3666-3672. (Pubitemid 30645223)
38. Labrie F, Belanger A, Belanger P, et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol. 2006; 99: 182-188. (Pubitemid 43766081)
39. Heracek J, Urban M, Sachova J, et al. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy. Neuro Endocrinol Lett. 2007; 28: 45-51. (Pubitemid 46291146)
40. Sinnnecker GH, Hiort O, Nitsche EM, Holterhus PM, Kruse K,. Functional assessment and clinical classification of androgen sensitivity in patients with mutations of the androgen receptor gene. German Collaborative Intersex Study Group. Eur J Pediatr. 1997; 156: 7-14. (Pubitemid 26425770)
41. Imamoto T, Suzuki H, Yano M, et al. The role of testosterone in the pathogenesis of prostate cancer. Int J Urol. 2008; 15: 472-480. (Pubitemid 351713199)
42. Miller LR, Partin AW, Chan DW, et al. Influence of radical prostatectomy on serum hormone levels. J Urol. 1998; 160: 449-453. (Pubitemid 29476696)
43. Lukkarinen O, Hammond GL, Kontturi M, Vihko R,. Peripheral and prostatic vein steroid concentrations in benign prostatic hypertrophy patients before and after removal of the adenoma. Scand J Urol Nephrol. 1980; 14: 225-227. (Pubitemid 11062027)
44. Lackner JE, Maerk I, Koller A, et al. Serum inhibin-not a cause of low testosterone levels in hypogonadal prostate cancer? Urology. 2008; 72: 1121-1124.
45. Risbridger GP, Shibata A, Ferguson KL, Stamey TA, McNeal JE, Peehl DM,. Elevated expression of inhibin alpha in prostate cancer. J Urol. 2004; 171: 192-196. (Pubitemid 37549121)
46. Hofland J, van Weerden WM, Dits NF, et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res. 2010; 70: 1256-1264.
47. Heracek J, Hampl R, Hill M, et al. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids. 2007; 72: 375-380. (Pubitemid 46452717)
48. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007; 67: 5033-5041. (Pubitemid 46910214)
49. Suzuki K, Nishiyama T, Hara N, Yamana K, Takahashi K, Labrie F,. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis. 2007; 10: 301-306. (Pubitemid 47351410)
50. Briganti A, Chun FK, Hutterer GC, et al. Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Eur Urol. 2007; 52: 733-743.